Skip to main content Skip to search Skip to main navigation

Quality Assurance – Current Status and Outlook

Excerpt from the GMP Compliance Adviser, Chapter 1.C Quality Assurance Duties

6 min. reading time | by Christian Gausepohl, PhD
Published in LOGFILE 21/2025 

What role does Quality Assurance play in the tension between consulting and monitoring, and between systemic and operational levels? What trends are emerging in the self-perception and role of modern quality assurance? Read more on this topic in Chapter 1.C Quality Assurance Duties in the GMP Compliance Adviser.


The overall role of Quality Assurance in companies varies and depends on many factors such as size, complexity, history, but also on the organization’s quality culture.

The trend here in the development of Quality Assurance is a movement from a coordinative and advisory function to a pronounced monitoring function. In principle, the move towards operational Quality Oversight in particular can offer a significant improvement for the quality culture, continuous improvement and the reduction of errors. This also offers the opportunity to integrate shop-floor QA operationally as part of lean management. 

Nevertheless, for each new Quality Assurance task – e.g. additional inspections or observation roles – the extent to which these are sensible, effective and efficient should be questioned. Above all, the definition of such measures should follow on the results of quality risk management. To this end, it must first be determined whether there is actually an unacceptable risk associated with an activity, e.g. a possible error with sufficient severity and reduced probability of detection.


The following example is intended to illustrate this:

Labels are to be applied to update the expiry date as part of a clinic sample production process. The labels are applied manually by employees in the Operations department. Correct application is verified by a second employee from the same department. Due to errors, further verification is now to be carried out through additional monitoring by the Quality Assurance department.

Correct labelling must be ensured to avoid risks for the patient. A second verification step can conceal possible weaknesses of the process and avoid faulty products in the finished product batch. The root cause of the problem is not being addressed, namely the process weakness of ensuring the detection in the initial verification step. The call from the Operational department for additional checks by QA – possibly to reduce its own workload – should therefore be critically scrutinized each time.


However, when setting standards and regulating their interpretation, Quality Assurance should also be aware that readjustments should actually serve the purpose of improvement. A clear distinction must be made here between "nice to have" and "need to have", i.e. whether this is really necessary or represents an embellishment of the requirement from a Quality Assurance perspective. Every adjustment should be clearly communicated to all stakeholders in advance. Examples include increasing requirements and more critical evaluation of documentation errors, e.g. readability and corrections. 

As in all companies and organizations, there is a risk that administrative processes will continue to grow and multiply over time, becoming more complex and detailed and thus increasing the demands on resources and processes. In this realm, Quality Assurance should always bear in mind that these tasks are not an end in themselves and that the management of processes should always be streamlined. 

Quality Assurance and its responsibilities are also part of the value chain. Without batch certification at the end of production, without the necessary steps, such as batch record review, product release is not possible. In addition, a successful Quality Assurance department contributes to the continuous improvement of processes and products within the scope of its tasks. Demonstrating this time and again is an important task in the cooperation between Operations and QA.


A common metric used by companies is the so-called cost of poor quality (Figure 1). It is intended to show the costs incurred by errors in the company. This can be helpful to emphasize and raise awareness of the importance of assuring quality and upholding standardized processes. Care should be taken to ensure that this metric is not seen as a reproach, but rather as an informative assessment of the current situation.

Figure 1 | Cost of Poor Quality


Ideally, Quality Assurance is both monitoring and consulting and also actively supporting the Operations departments. This active collaboration serves to yield and promote suggestions for improvement and result in their implementation. QA is not located in an "ivory tower" within the company but is an active partner for improvements and sustainable success. It should accompany and monitor processes and do the same for changes but not prevent them on principle. In risk management, QA ensures an honest and transparent assessment, even if this is not always the easiest way. In this way, Quality Assurance contributes to a positive development of the quality culture. 

Quality Assurance is a key pillar on which the Qualified Person bases their tasks and responsibilities. Cooperation is therefore naturally close.

What constitutes "good" quality assurance?
  • Monitoring and consulting
  • Active cooperation with the operational areas and providing support
  • Open, active support for improvements
  • Seeing themselves as part of the value chain
  • Not an “ivory tower” in the company, but a partner for improvements and sustainable success
  • Accompanying and observing processes and changes, not preventing changes
  • Ensuring honest risk management
  • Avoiding unnecessary readjustment of requirements
  • Streamlining administrative processes instead of increasing complexity
  • Important part of the management task to promote Quality Culture
  • Nurture the close cooperation between Quality Assurance and the Qualified Person

Figure 2 | Aspects of "good" quality assurance


Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

Dr. Christian Gausepohl
Dr. Christian Gausepohl

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next

Related Products

Skip product gallery
GMP Compliance Adviser | Named User Licence | 12M

GMP Compliance Adviser | Named User Licence | 12M

With an named user licence, one user can access the knowledge portal; with a corporate licence, any number of users can access it.Approx. 5,000 pages of practical GMP knowledge with illustrations and forms: Practical guidance for rapid implementation in the workplaceDetailed descriptions of GMP-compliant systemsInternational laws and guidelines Always up-to-date thanks to regular updates Download Advantages and Prices60+ Sample Documents In addition, the GMP Compliance Adviser contains more than 60 sample documents (MS Office) and practical examples that you can use.Sample SOPsSample FormsSample ReportsSample DocumentationChecklistsProcess Diagrams (Flowcharts)Practical Examples of QRM Application (e.g., Risk Analyses)Sample Documents for Qualification and ValidationCase StudiesWritten by more than 80 authors with hands-on experience directly linked to the industryA team of over 80 experts interpret regulatory requirements and describe how they are implemented in practice.The authors are experienced in the pharmaceutical industry, consulting, and government agencies.

delivery immediately after receipt of payment
€1,368.00 net excl. VAT
GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

Your knowledge portal for GDP-compliant pharmaceutical logistics.  It is important that you as a logistics service provider, but also as a client in the pharmaceutical industry, comply with regulatory requirements. The GMP:KnowHow knowledge portal guides you through the complex regulatory landscape of the pharmaceutical and logistical supply chain! The knowledge portal gives you an easy-to-understand overview of all the important topics. Interactive graphics help you navigate all areas covered by the EU GDP Guidelines (2013/C 343/01). You also have the relevant passages of the regulations directly at hand for each topic. This allows you to compare the requirements directly and saves valuable research time.One thing is certain: the knowledge portal answers your questions about the supply chain of medicinal products, active pharmaceutical ingredients and medical devices. You don't have to be an expert. Yet.You will find answers to your questions in the GMP:KnowHow Pharma Logistics (GDP). Where does GDP begin, where does GMP end? What does GDP-compliant mean? When do I also have to take GMP requirements into account? What permits do I need for certain activities? What requirements do I have to fulfil? What is the current legal basis? How am I covered? What authorizations do I have for my work, e.g. from my employer? Who is responsible — the client or the contractor? And many more What is the difference to the GMP Compliance Adviser? GMP:KnowHow Pharma Logistics (GDP) is a practical knowledge portal dedicated to Good Distribution Practice (GDP). It is a product that is independent of the GMP Compliance Adviser and concentrates on content that is essential for carriers of medicinal products, active pharmaceutical ingredients and medical devices as well as for logistics clients. The focus is on practical knowledge and how to apply it in your daily business. If necessary, the relevant regulations can be called up immediately alongside the practical knowledge, and you can see the relevant paragraphs at a glance. In addition, sample documents are available to help you make immediate progress. AuthorSimone Ferrante, currently Director Quality at Fisher Clinical Services, previously served as Head of Quality Control and Responsible Person (GDP) for the Grieshaber Group. She is also a long-standing author and GDP expert at GMP-Verlag.

delivery immediately after receipt of payment
€610.00 net excl. VAT
E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

Why are GMP rules important for technicians and engineers? Technicians and engineers play a key role in ensuring compliance with Good Manufacturing Practice (GMP) standards. They are involved in critical activities such as: planning and construction of ventilation systems, maintenance of water treatment plants, calibration of measuring sensors. Therefore, they are jointly responsible for the quality of medicines and must ensure that their work complies with GMP standards.Your advantages: Fast familiarization with GMP topics in approx. 2 hours, time- and location-independent online training, printable personal certificate, 12-month access for initial and follow-up training, automatic updates in case of legal changes,content compliant with Article 7(4) of Directive 2003/94/EC.The Author This e-learning course was developed with the collaboration of Dipl.-Ing. Andreas Nuhn (D & B Pharmadesign GmbH).

delivery time appr. 2-5 workdays after receipt of payment
€245.00 net excl. VAT
GMP Fundamentals | A Step-by-Step Guide

GMP Fundamentals | A Step-by-Step Guide

This handbook is a practical and easy to read guideline, giving you a quick and comprehensive overview of the complex world of Good Manufacturing Practice (GMP) without the need of previously acquired knowledge. Some topics are: GMP: Purpose and basic pharmaceutical terms Laws, licenses and inspections Personnel: Responsibility and hygiene Standard Operating Procedures (SOP) and documentation Design of rooms and facilities Processing and packaging Quality control and market release Suppliers, storage and logistics (Good Distribution Practice = GDP) Alphabetical index and abbreviations Using practical examples and comparisons to every-day life will help to easy understand GMP regulations.GMP Fundamentals is a helpful guide which facilitates the entry into the GMP world and teaches the necessary basics.

delivery immediately after receipt of payment
€44.90 net excl. VAT